Going deep into schizophrenia with artificial intelligence
Author
dc.contributor.author
Cortés Briones, Jose A.
Author
dc.contributor.author
Tapia Rivas, Nicolás Igor
Author
dc.contributor.author
D'Souza, Deepak Cyril
Author
dc.contributor.author
Estévez Valencia, Pablo Antonio
Admission date
dc.date.accessioned
2022-07-29T14:28:42Z
Available date
dc.date.available
2022-07-29T14:28:42Z
Publication date
dc.date.issued
2022
Cita de ítem
dc.identifier.citation
Schizophrenia Research 245 (2022) 122–140
es_ES
Identifier
dc.identifier.other
10.1016/j.schres.2021.05.018
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/187050
Abstract
dc.description.abstract
Despite years of research, the mechanisms governing the onset, relapse, symptomatology, and treatment of schizophrenia (SZ) remain elusive. The lack of appropriate analytic tools to deal with the heterogeneity and complexity of SZ may be one of the reasons behind this situation. Deep learning, a subfield of artificial intelligence (AI) inspired by the nervous system, has recently provided an accessible way of modeling and analyzing complex, high-dimensional, nonlinear systems. The unprecedented accuracy of deep learning algorithms in classification and prediction tasks has revolutionized a wide range of scientific fields and is rapidly permeating SZ research. Deep learning has the potential of becoming a valuable aid for clinicians in the prediction, diagnosis, and treatment of SZ, especially in combination with principles from Bayesian statistics. Furthermore, deep learning could become a powerful tool for uncovering the mechanisms underlying SZ thanks to a growing number of techniques designed for improving model interpretability and causal reasoning. The purpose of this article is to introduce SZ researchers to the field of deep learning and review its latest applications in SZ research. In general, existing studies have yielded impressive results in classification and outcome prediction tasks. However, methodological concerns related to the assessment of model performance in several studies, the widespread use of small training datasets, and the little clinical value of some models suggest that some of these results should be taken with caution.
es_ES
Patrocinador
dc.description.sponsorship
United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
Brain and Behavior Research Foundation
Wallace Foundation
CH TAC
Takeda Pharmaceutical Company Ltd
Roche Holding
Heffter Research Institute
ANID-Chile
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
Elsevier
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States